CareDx Navigates Crosscurrents of Strong Growth and Insider Selling

The investment narrative surrounding transplant diagnostics firm CareDx is one of stark contrasts. The company’s latest quarterly results revealed significant operational progress, yet this was immediately overshadowed by substantial stock sales from its top executives and persistent regulatory uncertainty, creating a complex picture for shareholders. The central question for investors is whether the underlying business strength can overcome these concerning signals.

Quarterly Performance: Robust Growth Amidst Losses

CareDx’s second-quarter 2025 financials presented a mixed bag. The company posted a solid 14% year-over-year increase in adjusted revenue, which reached $90.5 million and surpassed analyst expectations. However, this top-line strength was not reflected on the bottom line, as CareDx reported a GAAP net loss of $8.6 million for the period.

A key operational bright spot was the sustained growth in test volume. The company processed 49,500 tests, marking an eighth consecutive quarter of growth and a 13% increase year-over-year. This surge in activity contributed to a dramatic improvement in adjusted EBITDA, which swung to a positive $9.1 million from a near-breakeven result in the prior-year quarter.

Regulatory Overhang and Its Potential Impact

A significant cloud of uncertainty continues to hang over CareDx due to pending regulatory decisions. The commentary period for a pivotal Draft Local Coverage Determination (LCD) concerning reimbursement for molecular tests for transplant rejection closes today. This proposed regulation maintains coverage for surveillance testing in kidney, heart, and lung transplant patients but introduces a new bundled payment model.

The company has stated it will formally respond during the commentary process. A final ruling, which typically follows within a year, is poised to fundamentally shape the future profitability of CareDx’s core business model.

Should investors sell immediately? Or is it worth buying CareDx?

Leadership’s Actions Raise Eyebrows

Perhaps the most alarming development for the market has been the aggressive selling activity by corporate insiders. Over the past ninety days, multiple directors have offloaded significant portions of their holdings.

Director William A. Hagstrom reduced his stake by more than 26%. Fellow directors Hannah Valantine and Peter Maag sold tens of thousands of shares at prices ranging from $18.58 to $19.90. Transactions of this magnitude are rarely interpreted as a vote of confidence from those with the closest view of the company’s prospects.

A Cautious Outlook for the Year

Reflecting this uncertain environment, CareDx has issued a modest downward revision to its full-year guidance. The company now anticipates revenue in a narrower band of $367 million to $373 million. Its adjusted EBITDA forecast remains unchanged, projected to land between $29 million and $33 million.

The stock recently traded at €11.68, a price that sits approximately 60% below its 52-week high. While shares experienced a one-day bounce of over 4%, this rally appears fragile against the backdrop of fundamental regulatory challenges and a conspicuous lack of conviction from the company’s own leadership. The market is now left to ponder whether CareDx can successfully convert its operational momentum into sustainable profit or if the insider selling accurately presages tougher times ahead.